Skip to content
Diabetes
-
Novo Nordisk’s Rybelsus lowers MACE risk in Type 2 Diabetes patients with CKD
The SOUL trial met its primary objective by demonstrating a 14% reduction in the risk of major adverse cardiovascular events (MACE), which include cardiovascular death, nonfatal heart attacks, and nonfatal strokes, for patients treated with Rybelsus compared to those receiving a placebo.
-
-
-
-
-
-
-
-
-
